tiprankstipranks
CompuGroup Medical SE (GB:0MSD)
LSE:0MSD

CompuGroup Medical (0MSD) Income Statement

2 Followers

CompuGroup Medical Income Statement

Last quarter (Q4 2022), CompuGroup Medical's total revenue was €327.66M, an increase of 17.35% from the same quarter last year. In Q4, CompuGroup Medical's net income was €13.80M. See CompuGroup Medical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
€ 1.13B€ 1.13B€ 1.03B€ 837.26M€ 745.81M€ 717.02M
Cost of Revenue
€ 171.58M€ 171.58M€ 154.13M€ 124.31M€ 114.39M€ 132.92M
Gross Profit
€ 958.16M€ 958.16M€ 871.19M€ 712.95M€ 631.42M€ 584.11M
Operating Expense
€ 850.71M€ 850.70M€ 763.29M€ 587.59M€ 519.57M€ 442.22M
Operating Income
€ 107.46M€ 107.46M€ 107.90M€ 125.37M€ 111.85M€ 141.89M
Net Non Operating Interest Income Expense
€ 5.67M€ 7.05M€ -4.44M€ -6.14M€ -5.91M€ -5.00M
Other Income Expense
------
Pretax Income
€ 106.82M€ 106.82M€ 97.87M€ 110.43M€ 107.75M€ 134.10M
Tax Provision
€ 32.70M€ 32.70M€ 28.84M€ 37.01M€ 41.59M€ 37.76M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ 82.28M€ 73.41M€ 68.97M€ 73.19M€ 65.82M€ 96.08M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
€ 1.02B€ 1.02B€ 917.42M€ 711.89M€ 633.96M€ 575.14M
Net Income From Continuing And Discontinued Operation
€ 73.41M€ 73.41M€ 68.97M€ 73.19M€ 65.82M€ 96.08M
Normalized Income
€ 80.62M€ 80.13M€ 72.79M€ 75.73M€ 68.20M€ 97.58M
Interest Expense
€ 9.12M€ 9.12M€ 5.40M€ 6.36M€ 5.68M€ 6.41M
EBIT
€ 115.93M€ 115.93M€ 103.27M€ 116.78M€ 113.42M€ 140.51M
EBITDA
€ 228.26M€ 228.25M€ 213.99M€ 192.49M€ 176.28M€ 185.11M
Currency in EUR

CompuGroup Medical Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis